GENSCRIPT BIO (01548) saw its shares rise more than 5% in Hong Kong trading. At the time of writing, the stock was up 3.24%, trading at HKD 66.95, with a turnover of HKD 62.81 million.

The movement follows the company's release of its annual results for the period ended December 31, 2025, on March 15. The group reported revenue of $960 million, a significant increase of 61.4% year-over-year. However, the loss attributable to owners of the parent was $533 million, a shift from profit to loss compared to the previous year. The basic loss per share was 24.58 US cents.

The substantial revenue growth was primarily driven by a major increase in licensing revenue, alongside steady growth in other business segments. This revenue growth contributed to a sharp rise in the group's gross profit. The gross profit from continuing operations for the period was approximately $553 million, representing an increase of 103.3% over the prior period.

Huatai Securities noted that GENSCRIPT BIO's 2025 results were in line with expectations, with major business segments demonstrating either robust growth or a turnaround to profitability. The core product, CARVYKTI, from associate company Legend Biotech (LEGN), achieved sales of $1.887 billion in 2025, a 96% increase year-over-year. Furthermore, losses at Legend Biotech narrowed significantly to $33 million, with expectations for the company to achieve profitability in 2026, improving the overall profit outlook for GENSCRIPT BIO.